Quantcast
Home > Quotes > ACAD
ACAD

ACADIA Pharmaceuticals Inc. Common Stock (ACAD) Quote & Summary Data

$18.57
*  
0.21
1.12%
Get ACAD Alerts
*Delayed - data as of Dec. 11, 2018  -  Find a broker to begin trading ACAD now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ACAD Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
26
Today's High / Low
$ 19.13 / $ 18.35
Share Volume
839,626
50 Day Avg. Daily Volume
2,641,123
Previous Close
$ 18.78
52 Week High / Low
$ 32.99 / $ 12.77
Market Cap
2,322,634,523
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -2
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.41

Intraday Chart

Shares Traded

Share Volume:
839,626
50 Day Avg. Daily Volume:
2,641,123

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -2

Trading Range

The current last sale of $18.57 is 45.42% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 19.13 $ 32.99
 Low: $ 18.35 $ 12.77

ETFs with ACAD as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
2.03% SPDR Series Trust SPDR S&P Biotech ETF (XBI) -21.53 (-21.44%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system, or CNS, disorders. We have a portfolio of product opportunities led by our novel drug, NUPLAZID (pimavanserin), which was approved by the U.S. Food and Drug Administration, or FDA, on April 29, 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, or PD Psychosis, and is the only drug approved in the United States for this condition. NUPLAZID is a selective serotonin inverse agonist, or SSIA, preferentially targeting 5-HT2A receptors.  ... More ...  


Risk Grade

Where does ACAD fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 19.06
Open Date:
Dec. 11, 2018
Close Price:
$ 18.57
Close Date:
Dec. 11, 2018

Consensus Recommendation

Analyst Info